biotech · Advanced Solid Tumors · Tumor, Solid · EIKN
Eikon Therapeutics
Eikon Therapeutics is a biotech organization headquartered in Millbrae, USA. It trades on NYSE under ticker EIKN. Primary therapeutic focus areas include Advanced Solid Tumors, Tumor, Solid, Advanced Melanoma, Advanced s
230 Harriet Tubman Way, Millbrae, CA 94030, US HQ
2019 Founded
404 Employees
Public company Type
EIKN · NYSE Ticker
Company details
- Status
- Public
- HQ
- 230 Harriet Tubman Way, Millbrae, CA 94030, US
- Founded
- 2019
- Employees
- 404
- Programs
- 15
- Drugs
- 13
- Patents
- 4
Association atezolizumab + BDB001 + RT
Phase 2 · small molecule · Solid Tumor, Adult
Association atezolizumab + BDB001 + RT for Solid Tumor, Adult is a Phase 2 program (small_molecule) at Eikon Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code IB 2019-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Eikon Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Solid Tumor, Adult
- Status
- active
- Trials
- 1